Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids

被引:32
作者
Kennedy, WA
Laurier, C
Gautrin, D
Ghezzo, H
Paré, M
Malo, JL
Contandriopoulos, AP
机构
[1] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada
[2] Hop Sacre Coeur, Ctr Quebecois Excellence Sante Resp, Montreal, PQ H4J 1C5, Canada
[3] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[4] Univ Montreal, Grp Rech Interdisciplinaire Sante, Montreal, PQ, Canada
关键词
inhaled steroid; oral candidiasis; bronchial diseases; epidemiology;
D O I
10.1016/S0895-4356(99)00191-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Oral candidiasis (OC) is a frequent side effect of inhaled corticosteroids (iCSTs). This study estimated occurrence and significance of risk factors of OC treated with antifungals in users of iCSTs under conditions of normal use. This retrospective analysis used data drawn from drug insurance plan records in Quebec, Canada. The sample contained 27,000 seniors using anti-asthma medications during 1990. Three years of data (1989-1991) were searched for use of oral antifungals concurrent with exposure to iCSTs. A case-control study examined factors leading to increased probability of first incidence of OC in new users of iCSTs. Three-year occurrence for OC was 7%. Increased risk for a first occurrence of OC was significantly associated with higher doses of iCST, increased length of iCST exposure, use of antibiotics, use of oral steroids, having three or more prescribers, a history of use of both high and low strengths of iCST, and concurrent use of oral steroids and diabetes medications. The occurrence of OC is relatively high. Knowledge of factors leading to increased risk could facilitate the targetting of patients who need timely intervention, under conditions of normal use. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:696 / 701
页数:6
相关论文
共 27 条
[1]  
*BRIT THOR SOC, 1993, THORAX, V48, pS1
[2]  
CAYTON RM, 1974, LANCET 0810, P303
[3]  
CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
[4]   Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma [J].
Condemi, JJ ;
Chervinsky, P ;
Goldstein, MF ;
Ford, LB ;
Berger, WE ;
Ayars, GH ;
Rogenes, PR ;
Edwards, L ;
Pepsin, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (04) :467-474
[5]   CLINICAL COMPARISON OF INHALED BUDESONIDE DELIVERED EITHER VIA PRESSURIZED METERED DOSE INHALER OR TURBUHALER [J].
ENGEL, T ;
HEINIG, JH ;
MALLING, HJ ;
SCHARLING, B ;
NIKANDER, K ;
MADSEN, F .
ALLERGY, 1989, 44 (03) :220-225
[6]  
Ernst P., 1996, CAN RESPIR J, V3, P101
[7]  
GRANT IWB, 1974, LANCET, V2, P838
[8]  
HABBICK B, 1995, CAN MED ASSOC J, V153, P1437
[9]   THE ASSESSMENT AND TREATMENT OF ASTHMA - A CONFERENCE REPORT [J].
HARGREAVE, FE ;
DOLOVICH, J ;
NEWHOUSE, MT .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1990, 85 (06) :1098-1111
[10]   RATIONALE AND USE OF CORTICOSTEROIDS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
HUDSON, LD ;
MONTI, CM .
MEDICAL CLINICS OF NORTH AMERICA, 1990, 74 (03) :661-690